| Host: |
Rabbit |
| Applications: |
WB/ELISA/IHC |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Quinone oxidoreductase (275-325 aa) is suitable for use in Western Blot, ELISA and Immunohistochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-2000IHC-P 1:50-300ELISA 2000-20000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
CRYZ |
| Gene ID: |
1429 |
| Uniprot ID: |
QOR_HUMAN |
| Immunogen Region: |
275-325 aa |
| Specificity: |
This antibody detects endogenous levels of QOR at Human/Mouse/Rat |
| Immunogen: |
Synthesized peptide derived from the human QOR at the amino acid range 275-325 |
| Function | Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones, such as 1,2-naphthoquinone or 9,10-phenanthrenequinone, are the best substrates (in vitro). May act in the detoxification of xenobiotics. Interacts with (AU)-rich elements (ARE) in the 3'-UTR of target mRNA species. Enhances the stability of mRNA coding for BCL2. NADPH binding interferes with mRNA binding. |
| Protein Name | Quinone OxidoreductaseNadph -Quinone ReductaseZeta-Crystallin |
| Cellular Localisation | Cytoplasm |
| Alternative Antibody Names | Anti-Quinone Oxidoreductase antibodyAnti-Nadph -Quinone Reductase antibodyAnti-Zeta-Crystallin antibodyAnti-CRYZ antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
